Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Who We Help
  2. Insights
  3. Events
  4. Contact Us
MAIN/search
MAIN/Who We Help
Who We Help/
WHO WE HELP
  • Pharmaceutical Manufacturers
  • Emerging Biopharma
  • MedTech
  • Financial Institutions
  • Government and Public Health
  • Health Plans
  • Hospital and Health Systems
  • Insurers and Risk
  • Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers

Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.

Harness Data
Pharmaceutical Manufacturers
Emerging Biopharma (Global page)

Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.

Discover Innovations
MedTech

Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.

Explore MedTech
MedTech
Financial Institutions

Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.

Access Insights
Government and Public Health

Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.

Unlock Innovations
Government and Public Health
Health Plans

Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.

Navigate Health Plans
Hospital and Health Systems

Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.

Streamline Decisions
Hospital and Health Systems
Insurers and Risk

Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.

Evaluate Risk
Medical Specialty and Patient Advocacy

Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.

Enhance Your Specialty
MAIN/Insights
Insights/
U.S. PROGRESS POINT

A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.

LEARN MORE
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS

PODCASTS

"Discover the future through our enlightening podcasts available in the United States.

EXPLORE PODCASTS

FACT SHEET

"IQVIA AI Medical Record Review

LEARN MORE

BLOG

"Decoding DSCSA: Ensuring Compliance in the Pharmaceutical Supply Chain

READ MORE
MAIN/Events
Events/
ON-DEMAND WEBINARS

Visit our library of on-demand webinars.

WATCH ON-DEMAND WEBINARS
UPCOMING EVENTS & WEBINARS

View our upcoming events and webinars.

DISCOVER EVENTS & WEBINARS

EVENT

"26th Controlled Substances and State Regulatory Conference

REGISTER NOW
MAIN/Contact Us
Contact Us/
Livre Blanc
The 340B Drug Discount Program Exceeds $100B in 2022
Apr 14, 2023
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

This article is the latest in IQVIA's series of yearly reports on the size and growth of the 340B drug discount program. In 2022, 340B sales exceeded $100B in WAC dollars for the first time despite contract pharmacy restrictions imposed by manufacturers. Looking forward, 340B growth is likely to be influenced by continued developments in contract pharmacy restrictions and related court cases, the impact of the Inflation Reduction Act, recent changes in pricing strategies in the insulin market, and the possibility of expansion of the 340B patient definition. Download this white paper to learn more.

Related solutions

Market Access

Gain high value access and increase the profitability of your brands

Contact Us